SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Follow-up) — Elizabeth Barrett Browning — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientElizabeth Barrett Browning
Date of birth1806-03-06
IdentifiersMRN HR-NI026-SYN-TD; SSN (made up) 000-26-4157
Document date1845-06-15
AuthorClementine Haverford-Asante, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month review: final cultures, vitamin D, mood, safety, and the opioid dose. [S]

History of Present Illness

Ms. Barrett Browning returns three months after diagnosis. Her sputum is down to about a tablespoon a day and she has seen no blood since the first month. She had three nights of restlessness and lighter sleep after the first morphine step and then settled; she has taken no extra doses. She has had twelve grief therapy sessions and has begun to write about her brother, which she could not do before. She has gained almost 2 kg. She would like to take the next small step down. [S]

ElementDetail
LungsAbout a tablespoon of sputum a day; no blood; no exacerbation
Opioid step9 mg twice daily for eight weeks; three restless nights, then settled
Grief therapyTwelve sessions
Weight43.3 kg

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever; energy better
RespiratoryPositiveMorning cough with a little sputum; no blood
GastrointestinalNegativeStools regular; appetite better
PsychiatricNegativeMood lighter; no thoughts of self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Morphine sulfate 2 mg/mL oral solution, 5 mL (10 mg) by mouth twice daily, morning and bedtime (20 mg a day; long-standing prescription, continued)5 mL (10 mg) twice daily, morning and bedtimeOral route1838-03-01 to 1845-04-19completedS
Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose, repeat in 2 to 3 minutes in the other nostril if no response; call 911As needed for suspected overdose; keep two devices at homeNasal route1845-03-16activeS
Cholecalciferol (vitamin D3) 1000 unit (25 mcg) oral tablet, two tablets (1819 units) by mouth dailyTwo tablets dailyOral route1845-03-16activeS
Morphine sulfate 2 mg/mL oral solution, 4.5 mL (9 mg) by mouth twice daily, morning and bedtime (18 mg a day)4.5 mL (9 mg) twice daily, morning and bedtimeOral route1845-04-20 to 1845-06-14completedS
Morphine sulfate 2 mg/mL oral solution, 4 mL (8 mg) by mouth twice daily, morning and bedtime (16 mg a day)4 mL (8 mg) twice daily, morning and bedtimeOral route1845-06-15 to 1845-10-18completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1845-06-15Body height157cmS
1845-06-15Body weight43.3kgS
1845-06-15Body mass index (BMI) [Ratio]17.6kg/m2S
1845-06-15Systolic blood pressure106mm[Hg]S
1845-06-15Diastolic blood pressure66mm[Hg]S
1845-06-15Heart rate84/minS
1845-06-15Respiratory rate16/minS
1845-06-15Body temperature36.7CelS
1845-06-15Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1845-06-1525-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma34ng/mL30 to 100 ng/mL sufficient; below 20 ng/mL deficientNormalS
1845-06-15Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
1845-06-15Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]5{score}S

Physical Exam

Vital signs recorded on 1845-06-15; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 43.3 kg
RespiratoryA few crackles at the left base only
NeurologicalNot drowsy; no tremor, sweating or yawning
PsychiatricBrighter; speaks of her brother with sadness but without being overwhelmed; no suicidal ideation

Problems

ProblemClinical statusVerificationCodeProvenance
Chronic cough with daily yellow sputum, occasional streaks of blood, and breathlessness on stairs, worse in winter, for several years after an illness with blood in the sputum about eight years ago; tuberculosis, nontuberculous mycobacteria and bronchiectasis to be distinguishedresolvedconfirmed R05.3S — Synthetic presenting concern at the index visit, superseded by the diagnosis at the consultation; it echoes her documented chest illness (D).
Non-cystic fibrosis bronchiectasis of the left lower lobe and lingula with chronic Haemophilus influenzae infection and mild airflow obstruction (Bronchiectasis Severity Index 3, mild); tuberculosis and nontuberculous mycobacterial disease excluded; synthetic modern diagnosis chosen for a historical chest illness whose cause is disputedactiveconfirmed J47.9S — Synthetic modern diagnosis; the nature of her historical chest illness remains undetermined (R, disputed).
Long-term prescribed opioid therapy (oral morphine 20 mg a day for many years, for cough, sleeplessness and palpitations), with expected physiological dependence; no opioid use disorder on DSM-5-TR assessmentactiveconfirmed Z79.891S — Synthetic modern problem anchored to her documented prescribed opium (D); tolerance and withdrawal on prescribed opioids do not count toward opioid use disorder.
Prolonged grief disorder after the drowning of her closest brother five years ago, with yearning, self-blame, avoidance of reminders of the sea, and depressive symptoms (PHQ-9 12); no suicidal ideationactiveconfirmed F43.81S — Synthetic modern diagnosis anchored to her documented bereavement (D); not a claim about her real mental health.
Vitamin D deficiency (25-hydroxyvitamin D 15 ng/mL) in a woman who rarely goes outdoorsresolvedconfirmed E55.9S — Synthetic finding at intake; repleted by twelve weeks.
Underweight (BMI 16.8) with a small appetiteactiveconfirmed R63.6S — Synthetic finding at intake.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryMycobacterial culture including nontuberculous mycobacteriaAt diagnosis (final at six to eight weeks), then yearly and with unexplained declineCompleted todayFinal at eight weeks: no growth of Mycobacterium tuberculosis or nontuberculous mycobacteria; next yearly
LaboratorySputum bacterial cultureAt each review and at every exacerbation, before antibioticsCompleted todayNormal flora only
Self-managementAirway clearance technique and exerciseEvery visitCompleted todayTwice daily; sputum about a tablespoon a day
Self-managementExacerbations: number in the past year, written plan, and rescue antibioticEvery visitCompleted todayNone since diagnosis
Self-managementHemoptysis: amount, and when to seek emergency careEvery visitCompleted todayNone since the first month
ImagingSpirometry and Bronchiectasis Severity IndexAt diagnosis, then yearlyUp to dateNext at one year
Medication safetyOpioid benefits and harms: function, sleep, cough, sedation, breathing, constipation, and her goalsEvery visit, and at least every three monthsCompleted todayNo sedation; sleep and function better; second step chosen
Medication safetyDose reduction at her request: withdrawal symptoms and sleepFour weeks after each stepCompleted todayThree restless nights after the first step, then settled; no extra doses
Medication safetyPrescription drug monitoring program checkWith every prescription, and at least every three monthsCompleted todayOne prescriber, one pharmacy
Medication safetyUrine drug testAt the start of review, then at least yearlyUp to dateConsistent with morphine only at intake; next at one year
Medication safetyNaloxone at home, and no benzodiazepines or other sedativesEvery visitCompleted todayNaloxone in date at home; no sedatives
SurveyPHQ-9At least monthly during active treatment (CMID)Completed today7, from 10; GAD-7 5
ExaminationSuicide risk review and safety planEvery visitCompleted todayNo suicidal ideation; plan current
Self-managementGrief therapy attendance and responseWeekly for sixteen sessionsCompleted todayTwelve sessions attended
Laboratory25-hydroxyvitamin DTwelve weeks after starting replacement, then yearly; target 30 ng/mL or more (CMID)Completed today34 ng/mL; next yearly
ExaminationWeight and BMIEvery visitCompleted today43.3 kg, BMI 17.6

Goal progress:

Guideline basis: British Thoracic Society Guideline for Bronchiectasis in Adults (2019); Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017); Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline (2020); CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022); Shear MK, et al. Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial (2016); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression and osteoporosis monographs (2026)

Follow-up: Preventive visit next month. Seven-month review in the autumn with the PHQ-9, sputum culture, the influenza vaccine and the next opioid decision. Emergency care for more than a few teaspoons of blood. Next scheduled visit 1845-07-13: periodic adult preventive visit. [S]